Jamie Dimon Says He Has Seen the Numbers and SpaceX’s Orbital Data Centers ‘Could Actually Work’ Despite
Dimon Sees Orbital Computing’s Economic Potential Speaking on “The Master Investor Podcast with Wilfred Frost,” Dimon called SpaceX…
What’s Going On With Novo Nordisk Stock Thursday? – Novo Nordisk (NYSE:NVO)
Oral Semaglutide Shows Superior Glycaemic Control The phase 3a study evaluated oral semaglutide in patients aged 10–17 years…
Novo Nordisk Extends Lead As Eli Lilly New Obesity Pill Sees Modest Launch Uptake – Eli Lilly (NYSE:LLY)
Early Prescription Trends Show Slower Start For Lilly Reuters, citing IQVIA data, reported that Eli Lilly recorded 1,390…
Oklo CEO Says Nuclear Powers Everything ‘That’s Cool In Space’ – Oklo (NYSE:OKLO)
Everything Cool Needs Nuclear When asked if goals for nuclear-powered space exploration were far-fetched, DeWitte argued nuclear power…
Eli Lilly Just Launched Its $149 Obesity Pill – Eli Lilly (NYSE:LLY)
Eli Lilly and Co. (NYSE:LLY) on Wednesday announced that Foundayo (orforglipron) is now available to adults with obesity…
BlackRock’s Larry Fink Says Oil Could Slip Below $50 If The War Results In ‘Neutralized’ Iran: ‘Great Probability’ – BlackRock (NYSE:BLK)
BlackRock Inc. (NYSE:BLK) CEO Larry Fink expressed his belief that the ongoing U.S.-Iran conflict will not have lasting economic consequences, even…
Novo Nordisk Sued Over Alleged Scheme To Delay Generic Victoza In Favor Of Ozempic – Novo Nordisk (NYSE:NVO)
Novo Nordisk A/S (NYSE:NVO) is accused of unlawfully extending its monopoly over its diabetes drug Victoza through a…
Novo Nordisk Will Soon Reveal Whether Its GLP-1 Drug Can Slow Alzheimer’s – Novo Nordisk (NYSE:NVO)
Upcoming data from Novo Nordisk A/S (NYSE:NVO) early next month could offer the clearest signal yet on whether…
Novo Nordisk Leans Into Affordability Amid Rising Competition – Novo Nordisk (NYSE:NVO)
Novo Nordisk A/S (NYSE:NVO) announced on Monday that Wegovy (semaglutide) injection 0.25 mg and 0.5 mg and Ozempic are…
AI Bubble Fear? This Sector Is Quietly Surging While Tech Sinks – Amgen (NASDAQ:AMGN), Bristol-Myers Squibb (NYSE:BMY)
It hasn’t been an easy stretch for technology and AI stocks, with triple-digit year-to-date gainers like Palantir Technologies…
Novo Nordisk’s $100 Million Coramitug Shows Promise In Reducing Heart Failure Biomarker – Novo Nordisk (NYSE:NVO)
In a presentation at the American Heart Association’s (AHA’s) 2025 Scientific Sessions, researchers on Tuesday shared data from…
Wegovy And Zepbound Cost Effective But They Could Break Drug Budgets – Novo Nordisk (NYSE:NVO), Eli Lilly (NYSE:LLY)
The Institute for Clinical and Economic Review (ICER) on Tuesday released a Draft Evidence Report assessing the comparative…